Received Sep 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 1 | — | — |
Vision problems; Blurred vision - it occurs temporarily lasts for a few seconds and then goes back to normal; Headache; This spontaneous case was reported by a consumer and describes the occurrence of VISUAL IMPAIRMENT (Vision problems), VISION BLURRED (Blurred vision - it occurs temporarily lasts for a few seconds and then goes back to normal) and HEADACHE (Headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VISUAL IMPAIRMENT (Vision problems), VISION BLURRED (Blurred vision - it occurs temporarily lasts for a few seconds and then goes back to normal) and HEADACHE (Headache). At the time of the report, VISUAL IMPAIRMENT (Vision problems) and VISION BLURRED (Blurred vision - it occurs temporarily lasts for a few seconds and then goes back to normal) was resolving and HEADACHE (Headache) outcome was unknown. No concomitant medications were reported. Patient went to the ophthalmologist and neurologist who confirmed of patient having no vision and neurogenic problem. Patient is using butox for treatment of headache. This case was linked to MDEM21-03211, MDEDM21-03230 (Patient Link). Most recent FOLLOW-UP information incorporated above includes: On 17-Sep-2021: Upon internal review the case was reassessed and determined to be valid, hence significant correction was performed on 29-Aug-2025. On 23-Sep-2021: follow up received and contain NNI